April 22 (Bloomberg) -- GlaxoSmithKline Plc will release the first study to compare its cervical cancer vaccine with Merck & Co.’s blockbuster Gardasil, more than a year after completing the research.
.../...
It will be presented for the first time at a medical meeting in Malmoe, Sweden, on May 10, according to a draft of the program obtained by Bloomberg News. .../...
The study also will help governments determine which of the vaccines to select for immunizing women, influencing a global market that Glaxo estimated at more than $10 billion last year. Glaxo’s shot, used less often than Gardasil in Europe, hasn’t won approval in the U.S., where Merck began selling its version three years ago.
Entradas
No hay comentarios:
Publicar un comentario